What is HC Wainwright’s Forecast for Opthea FY2025 Earnings?

Opthea Limited (NASDAQ:OPT) – Stock analysts at HC Wainwright upped their FY2025 earnings estimates for Opthea in a research note issued on Tuesday, March 25th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($1.44) for the year, up from their prior forecast of ($1.60). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Opthea’s FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.24 EPS.

OPT has been the subject of several other reports. Canaccord Genuity Group upgraded Opthea to a “strong-buy” rating in a report on Tuesday, December 17th. Oppenheimer downgraded shares of Opthea from an “outperform” rating to a “market perform” rating in a report on Monday. Leerink Partnrs lowered shares of Opthea from a “strong-buy” rating to a “hold” rating in a research note on Monday. Jefferies Financial Group reissued an “underperform” rating and set a $1.00 price objective (down previously from $8.00) on shares of Opthea in a research report on Tuesday. Finally, Leerink Partners cut shares of Opthea from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $12.00 to $1.00 in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, Opthea currently has an average rating of “Hold” and a consensus price target of $1.33.

Opthea Stock Performance

OPT opened at $3.41 on Thursday. The company has a fifty day simple moving average of $4.41 and a 200 day simple moving average of $4.06. Opthea has a 12 month low of $1.79 and a 12 month high of $6.30.

Hedge Funds Weigh In On Opthea

Several hedge funds have recently modified their holdings of OPT. Jane Street Group LLC bought a new position in shares of Opthea in the third quarter valued at $114,000. ABC Arbitrage SA acquired a new stake in Opthea in the fourth quarter valued at $40,000. Citadel Advisors LLC bought a new position in shares of Opthea in the 4th quarter valued at about $79,000. Hsbc Holdings PLC acquired a new position in shares of Opthea during the 4th quarter worth about $556,000. Finally, OLD Mission Capital LLC bought a new stake in shares of Opthea in the 4th quarter valued at about $42,000. Institutional investors own 55.95% of the company’s stock.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.